Skip to main content
SpringerLink
Log in

Clinical Detection and Treatment of Pancreatic Neuroendocrine Tumors

  • Chapter
  • First Online:
Molecular Pathology of Endocrine Diseases

Part of the book series: Molecular Pathology Library ((MPLB,volume 3))

Abstract

Pancreatic endocrine neoplasms (PEN) typically generate a great deal of clinician interest because of the rarity with which they occur and their associated hormonal syndromes. While their rarity has limited research efforts into the pathophysiology of these tumors to some extent, recent advances in molecular biology techniques have allowed investigators to provide new insights into the pathogenesis of these lesions allowing the development of novel techniques for the diagnosis, localization, and treatment of PENs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Stridsberg M, Oberg K, Li Q, Engstrom U, Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol. 1995;144(1):49–59.

    Article  CAS  PubMed  Google Scholar 

  2. Nobels FR, Kwekkeboom DJ, Bouillon R, Lamberts SW. Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur J Clin Invest. 1998;28(6):431–440.

    Article  CAS  PubMed  Google Scholar 

  3. Nobels FR, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab. 1997;82(8):2622–2628.

    Article  CAS  PubMed  Google Scholar 

  4. Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999;86(5):858–865.

    Article  CAS  PubMed  Google Scholar 

  5. Tomassetti P, Migliori M, Simoni P, et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol. 2001;13(1):55–58.

    Article  CAS  PubMed  Google Scholar 

  6. Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997;8(7):685–690.

    Article  CAS  PubMed  Google Scholar 

  7. Adrian TE, Bloom SR, Bryant MG, Polak JM, Heitz PH, Barnes AJ. Distribution and release of human pancreatic polypeptide. Gut. 1976;17(12):940–944.

    Article  CAS  PubMed  Google Scholar 

  8. Bloom SR, Adrian TE, Polak JM. Pancreatic polypeptide from pancreatic endocrine tumours. Lancet. 1980;2(8202):1026.

    Article  CAS  PubMed  Google Scholar 

  9. Oberg K, Grimelius L, Lundqvist G, Lorelius LE. Update on pancreatic polypeptide as a specific marker for endocrine tumours of the pancreas and gut. Acta Med Scand. 1981;210(3):145–152.

    CAS  PubMed  Google Scholar 

  10. Srivastava A, Padilla O, Fischer-Colbrie R, Tischler AS, Dayal Y. Neuroendocrine secretory protein-55 (NESP-55) expression discriminates pancreatic endocrine tumors and pheochromocytomas from gastrointestinal and pulmonary carcinoids. Am J Surg Pathol. 2004;28(10):1371–1378.

    Article  PubMed  Google Scholar 

  11. Stridsberg M, Eriksson B, Oberg K, Janson ET. A panel of 11 region-specific radioimmunoassays for measurements of human chromogranin A. Regul Pept. 2004;117(3):219–227.

    Article  CAS  PubMed  Google Scholar 

  12. Oberg K. Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment. Curr Opin Oncol. 2005;17(4):386–391.

    Article  PubMed  Google Scholar 

  13. Li S, Beheshti M. The radionuclide molecular imaging and therapy of neuroendocrine tumors. Curr Cancer Drug Targets. 2005;5(2):139–148.

    Article  CAS  PubMed  Google Scholar 

  14. Virgolini I, Traub T, Leimer M, et al. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. Q J Nucl Med. 2000;44(1):50–58.

    CAS  PubMed  Google Scholar 

  15. Breeman WA, Kwekkeboom DJ, Kooij PP, et al. Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J Nucl Med. 1995;36(4):623–627.

    CAS  PubMed  Google Scholar 

  16. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20(8):716–731.

    Article  CAS  PubMed  Google Scholar 

  17. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27(3):273–282.

    Article  CAS  PubMed  Google Scholar 

  18. Virgolini I, Patri P, Novotny C, et al. Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol. 2001;12(suppl 2):S41-S45.

    Article  PubMed  Google Scholar 

  19. Kwekkeboom DJ, Bakker WH, Kooij PP, et al. [177Lu-DOT-AOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med. 2001;28(9):1319–1325.

    Article  CAS  PubMed  Google Scholar 

  20. Virgolini I, Raderer M, Kurtaran A, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med. 1994;331(17):1116–1121.

    Article  CAS  PubMed  Google Scholar 

  21. Thakur ML, Marcus CS, Saeed S, et al. 99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans. J Nucl Med. 2000;41(1):107–110.

    CAS  PubMed  Google Scholar 

  22. Wank SA. G protein-coupled receptors in gastrointestinal physiology I CCK receptors: an exemplary family. Am J Physiol. 1998;274(4 Pt 1):G607-G613.

    CAS  PubMed  Google Scholar 

  23. Behr TM, Jenner N, Radetzky S, et al. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med. 1998;25(4):424–430.

    Article  CAS  PubMed  Google Scholar 

  24. Reubi JC, Waser B, Schaer JC, et al. Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur J Nucl Med. 1998;25(5):481–490.

    Article  CAS  PubMed  Google Scholar 

  25. Kwekkeboom DJ, Bakker WH, Kooij PP, et al. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med. 2000;27(9):1312–1317.

    Article  CAS  PubMed  Google Scholar 

  26. Kaltsas G, Rockall A, Papadogias D, Reznek R, Grossman AB. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol. 2004;151(1):15–27.

    Article  CAS  PubMed  Google Scholar 

  27. Bombardieri E, Seregni E, Villano C, Chiti A, Bajetta E. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med Mol Imaging. 2004;48(2):150–163.

    CAS  PubMed  Google Scholar 

  28. Sundin A, Eriksson B, Bergstrom M, Langstrom B, Oberg K, Orlefors H. PET in the diagnosis of neuroendocrine tumors. Ann N Y Acad Sci. 2004;1014:246–257.

    Article  CAS  PubMed  Google Scholar 

  29. Koopmans KP, Neels OC, Kema IP, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol. 2008;26(9):1489–1495.

    Article  PubMed  Google Scholar 

  30. Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med. 2002;32(2):110–122.

    Article  PubMed  Google Scholar 

  31. Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002;32(2):123–132.

    Article  PubMed  Google Scholar 

  32. Buscombe JR, Caplin ME, Hilson AJ. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med. 2003;44(1):1–6.

    CAS  PubMed  Google Scholar 

  33. Wiseman GA, Kvols LK. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Semin Nucl Med. 1995;25(3):272–278.

    Article  CAS  PubMed  Google Scholar 

  34. Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol. 2007;46(6):723–734.

    Article  PubMed  Google Scholar 

  35. de Jong M, Breeman WA, Bakker WH, et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res. 1998;58(3):437–441.

    PubMed  Google Scholar 

  36. Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0), Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30(3):417–422.

    Article  CAS  PubMed  Google Scholar 

  37. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46(suppl 1):62S-66S.

    CAS  PubMed  Google Scholar 

  38. Oddstig J, Bernhardt P, Nilsson O, Ahlman H, Forssell-Aronsson E. Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro. Nucl Med Biol. 2006;33(7):841–846.

    Article  CAS  PubMed  Google Scholar 

  39. Capello A, Krenning E, Bernard B, Reubi JC, Breeman W, de Jong M. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2005;32(11):1288–1295.

    Article  CAS  PubMed  Google Scholar 

  40. Rogers BE, Zinn KR, Lin CY, Chaudhuri TR, Buchsbaum DJ. Targeted radiotherapy with [(90)Y]-SMT 487 in mice bearing human nonsmall cell lung tumor xenografts induced to express human somatostatin receptor subtype 2 with an adenoviral vector. Cancer. 2002;94(4 suppl):1298–1305.

    Article  CAS  PubMed  Google Scholar 

  41. Freeman SM, Abboud CN, Whartenby KA, et al. The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53(21):5274–5283.

    CAS  PubMed  Google Scholar 

  42. ter Horst M, Verwijnen SM, Brouwer E, et al. Locoregional delivery of adenoviral vectors. J Nucl Med. 2006;47(9):1483–1489.

    PubMed  Google Scholar 

  43. de Visser M, Verwijnen SM, de Jong M. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy. Cancer Biother Radiopharm. 2008;23(2):137–157.

    Article  PubMed  Google Scholar 

  44. Hofland LJ, Capello A, Krenning EP, de Jong M, van Hagen MP. Induction of apoptosis with hybrids of Arg-Gly-Asp molecules and peptides and antimitotic effects of hybrids of cytostatic drugs and peptides. J Nucl Med. 2005;46(suppl 1):191S-198S.

    CAS  PubMed  Google Scholar 

  45. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008;26(8):1316–1323.

    Article  CAS  PubMed  Google Scholar 

  46. Yao JC. Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab. 2007;21(1):163–172.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrine Surgery, The Cleveland Clinic, Cleveland, OH, USA

    Jamie C. Mitchell MD (Staff Surgeon)

Authors
  1. Jamie C. Mitchell MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pathology Service, WRN202, Massachusetts General Hospital, Fruit Street 55, Boston, 02114, USA

    Jennifer L. Hunt

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Mitchell, J.C. (2010). Clinical Detection and Treatment of Pancreatic Neuroendocrine Tumors. In: Hunt, J. (eds) Molecular Pathology of Endocrine Diseases. Molecular Pathology Library, vol 3. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-1707-2_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-1707-2_22

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4419-1706-5

  • Online ISBN: 978-1-4419-1707-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation